Adimmune Corporation (TWSE: 4142) today signed a NT$4.5 billion syndicated loan agreement with a consortium of ten banks led by Land Bank of Taiwan. Reflecting strong confidence in Adimmune’s growth prospects and recognition of vaccines as a strategically critical industry, the facility was oversubscribed by 150%, demonstrating robust support from the financial sector.   

The agreement was signed by Chairman Chi-Shean Chan of Adimmune and President Chih-Chien Chang of Land Bank of Taiwan. In addition to Land Bank as the lead arranger, participating institutions include First Commercial Bank, Mega International Commercial Bank, Entie Commercial Bank, Taiwan Cooperative Bank, Agricultural Bank of Taiwan, Chang Hwa Bank, Bank of Panhsin, Taiwan Business Bank, and Taichung Bank. Despite the strong oversubscription, the loan size was maintained at NT$4.5 billion in accordance with the lead bank’s recommendation. The proceeds will be used to support business expansion and working capital needs.   

President Chang noted that the vaccine industry is closely tied to national security and pandemic preparedness, adding that financial institutions are committed to supporting enterprises that contribute positively to society. Chairman Chan emphasized that the oversubscription reflects strong recognition of Adimmune. He added that the company will prudently deploy the funds and continue to strengthen its position within the global pandemic prevention framework. Chairman Chan further highlighted that this marks the fourth syndicated loan Adimmune has arranged with Land Bank-led consortia since 2011.   

Adimmune is currently the only vaccine manufacturer in Taiwan certified by both the European Union and the U.S. Food and Drug Administration. Given the capital- and talent-intensive nature of the vaccine industry, this round of financing strengthens Adimmune’s ability to pursue collaborations with global pharmaceutical companies and to participate in vaccine development and manufacturing at an international level.   

Adimmune noted that its influenza vaccines supply nearly 50% of Taiwan’s publicly funded seasonal influenza vaccination program each year. The company has also expanded exports to Southeast Asia and Eastern Europe and is currently seeking regulatory approval in Brazil, having already passed Brazilian GMP inspections, with the aim of entering the Southern Hemisphere market.   

In addition, Adimmune produces Taiwan’s only domestically licensed tetanus toxoid vaccine, capable of supplying at least one million doses annually.    

Separately, the domestically developed EV71 vaccine by Enimmune Corp. (a subsidiary of Adimmune) received regulatory approval in Taiwan in 2023. In 2025, full Phase III clinical data demonstrated a vaccine efficacy of 99.21%. The company is actively expanding into Southeast Asia, with regulatory filings in Macau, Vietnam, and Thailand, and has entered into a commercialization agreement with Etana Biotechnologies Indonesia, the largest private biopharmaceutical company in Indonesia, to strengthen its presence in the ASEAN market.   

Adimmune said it signed a Standard Material Transfer Agreement 2 (SMTA2) with the World Health Organization in 2024, allowing access to biological materials for pandemic response.   

Adimmune’s influenza vaccine, tetanus vaccine, and EV71 vaccine have all been included in the WHO full vaccine product list, which is designed to strengthen national and regional preparedness and improve vaccine accessibility.